Significant gastrointestinal bleeding in patients at risk of coronary stent thrombosis

Reviews in Cardiovascular Medicine

Volumn 10, Issue 1, 2009, Pages 14-24

  Dai, Xuming ^a   Makaryus, Amgad N ^a   Makaryus, John N ^a   Jauhar, Rajiv ^a  

^a North Shore Long Island Jewish Health System ^*  (United States)

Author keywords

Antiplatelet agents; Gastrointestinal bleeding; Percutaneous coronary intervention; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; ESOMEPRAZOLE; HEMOGLOBIN; PACLITAXEL; PROTEIN C; PROTEIN S; PROTON PUMP INHIBITOR; RAPAMYCIN; TICLOPIDINE; ANTIINFECTIVE AGENT; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE;

ACUTE CORONARY SYNDROME; ANGIOPLASTY; ANTICOAGULANT THERAPY; ARTERIOVENOUS MALFORMATION; BARE METAL STENT; BRACHYTHERAPY; BREAST CANCER; CELL PROLIFERATION; CELL PROTECTION; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; CORONARY STENT; DEATH; DIABETES MELLITUS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESISTANCE; DRUG WITHDRAWAL; ENDOSCOPY; ERADICATION THERAPY; ESOPHAGOGASTRODUODENOSCOPY; FAMILY HISTORY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HELICOBACTER INFECTION; HEMODYNAMIC MONITORING; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY FAILURE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LOADING DRUG DOSE; LONG TERM CARE; LOW DRUG DOSE; MEDICAL HISTORY; MELENA; PALLOR; PATHOPHYSIOLOGY; PEPTIC ULCER BLEEDING; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RESTENOSIS; REVIEW; RISK FACTOR; SMOOTH MUSCLE FIBER; STENT THROMBOSIS; STROKE; THROMBOCYTE AGGREGATION; ULCEROGENESIS; UNITED STATES; UNSTABLE ANGINA PECTORIS; UPPER GASTROINTESTINAL BLEEDING; WEAKNESS; AGED; CASE REPORT; CHEMICALLY INDUCED DISORDER; DUODENUM ULCER; FEMALE; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER PYLORI; INSTRUMENTATION; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; RISK ASSESSMENT; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTI-BACTERIAL AGENTS; ASPIRIN; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; DUODENAL ULCER; ENDOSCOPY, GASTROINTESTINAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER HEMORRHAGE; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PROTON PUMP INHIBITORS; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 66149122999     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Hill RA, Dundar Y, Bakhai A, et al. Drug-eluting stents: an early systematic review to inform policy. Eur Heart J. 2004;25:902-919. (Pubitemid 38857864)
2. Krumholz HM, Anderson JL, Brooks NH, et al. ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-Elevation Myocardial Infarction). Circulation. 2006;113:732-761. (Pubitemid 43754337)
3. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113:e166-e286.
4. Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation. 2005;111:2560-2564. (Pubitemid 40740853)
5. Longstreth KL, Wertz JR. High-dose clopidogrel loading in percutaneous coronary intervention. Ann Pharmacother. 2005;39:918-922. (Pubitemid 40570671)
6. Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2005;111:2099-2106. (Pubitemid 40577905)
7. von Beckerath N, Taubert D, Pogatsa-Murray G, et al. A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite. Thromb Haemost. 2005;93:789-791. (Pubitemid 40485419)
8. Honda Y, Fitzgerald PJ. Stent thrombosis: an issue revisited in a changing world. Circulation. 2003;108:2-5. (Pubitemid 36859010)
9. Karrillon GJ, Morice MC, Benveniste E, et al. Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy: 30-day clinical outcome of the French Multicenter Registry. Circulation. 1996;94:1519-1527. (Pubitemid 26320253)
10. Moussa I, Di Mario C, Reimers B, et al. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol. 1997;29:6-12. (Pubitemid 27028713)
11. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001;103:1967-1971.
12. Cheneau E, Leborgne L, Mintz GS, et al. Predictors of subacute stent thrombosis: results of a systemic intravascular ultrasound study. Circulation. 2003;108:43-47. (Pubitemid 36859018)
13. Serruys PW, Unger F, Sousa JE. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease [comment]. N Engl J Med. 2001:344:1117-1124. (Pubitemid 32285232)
14. Werner GS, Gastmann O, Ferrari M, et al. Risk factors for acute and subacute stent thrombosis after high-pressure stent implantation: a study by intracoronary ultrasound. Am Heart J. 1998;135:300-309. (Pubitemid 28139172)
15. De Servi S, Repetto S, Klugmann S, et al. Stent thrombosis: incidence and related factors in the RISE Registry (Registro Impianto Stent Endocoronarico). Catheter Cardiovasc Interv. 1999;46:13-18. (Pubitemid 29024505)
16. Schuhlen H, Kastrati A, Dirschinger J, et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation. 1998;98:104-111. (Pubitemid 28317889)
17. Kereiakes DJ, Choo JK, Young JJ, Broderick TM. Thrombosis and drug-eluting stents: a critical appraisal. Rev Cardiovasc Med. 2004;5:9-15. (Pubitemid 38344495)
18. Wang F, Stouffer GA, Waxman S, Uretsky BF. Late coronary stent thrombosis: early vs. late stent thrombosis in the stent era. Catheter Cardiovasc Interv. 2002;55:142-147. (Pubitemid 34127369)
19. Farb A, Burke AP, Kolodgie FD, Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation. 2003;108:1701-1706. (Pubitemid 37243657)
20. Waksman R, Ajani AE, White RL, et al. Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS). Circulation. 2001;103:2332-2335. (Pubitemid 32448795)
21. Ajani AE, Cheneau E, Leborgne L, et al. Late thrombosis: a problem solved? J Interv Cardiol. 2003;16:9-13. (Pubitemid 36293088)
22. Wessely R, Schomig A, Kastrati A. Sirolimus and paclitaxel on polymer-based drug-eluting stents: similar but different. J Am Coll Cardiol. 2006;47:708-714. (Pubitemid 43243089)
23. Schampaert E, Cohen EA, Schluter M, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004;43:1110-1115. (Pubitemid 38352997)
24. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003;362:1093-1099. (Pubitemid 37222332)
25. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323. (Pubitemid 37186209)
26. Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol. 2005;45:947-953. (Pubitemid 40342824)
27. US Food and Drug Administration. FDA public health web notification: final update of information for physicians on sub-acute thromboses (SAT) and hypersensitivity reactions with use of the Cordis Cypher™ sirolimus-eluting coronary stent. http://www.fda.gov/cdrh/safety/cypher3.html. Issued October 18, 2004. Accessed December 23, 2008.
28. Jeremias A, Sylvia B, Bridges J, et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation. 2004;109:1930-1932. (Pubitemid 38544480)
29. Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med. 2005;353:653-662. (Pubitemid 41175673)
30. Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation. 2006;113:1108-1113. (Pubitemid 43754278)
31. Pandhi P, Shafiq N, Malhotra S. Drug-eluting stents do not increase the risk of stent thrombosis, but longer stents may be associated with greater incidence of thrombosis. Commentary. Evid Based Cardiovasc Med. 2005;9:184-186. (Pubitemid 41150062)
32. Moreno R, Fernández C, Macaya C. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies: reply [letter]. J Am Coll Cardiol. 2006;47:214-215.
33. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data). Am J Cardiol. 2005;95:1469-1472.
34. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis. J Am Coll Cardiol. 2005;45:941-946. (Pubitemid 40342823)
35. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519-1521. (Pubitemid 39410418)
36. Zimarino M, Renda G, Maddestra N, De Caterina R. Late coronary thrombosis after drugeluting stent: stent vs patient-driven prescription of aspirin-clopidogrel combination. Thromb Haemost. 2004;92:668-669. (Pubitemid 39248027)
37. Takano M, Mizuno K. Late coronary thrombosis in a sirolimus-eluting stent due to the lack of neointimal coverage. Eur Heart J. 2006;27:1133. (Pubitemid 43752379)
38. Stabile E, Cheneau E, Kinnaird T, et al. Late thrombosis in cypher stents after the discontinuation of antiplatelet therapy. Cardiovasc Radiat Med. 2004;5:173-176. (Pubitemid 44556561)
39. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-2130. (Pubitemid 40617065)
40. Collet JP, Montalescot G, Blanchet B, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation. 2004;110:2361-2367. (Pubitemid 39407340)
41. Ong AT, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol. 2005;45:2088-2092. (Pubitemid 40814135)
42. Waters RE, Kandzari DE, Phillips HR, et al. Late thrombosis following treatment of in-stent restenosis with drug-eluting stents after discontinuation of antiplatelet therapy. Catheter Cardiovasc Interv. 2005;65:520-524. (Pubitemid 41060757)
43. Rodriguez AE, Mieres J, Fernandez-Pereira C, et al. Coronary stent thrombosis in the current drug-eluting stent era: insights from the ERACI III trial. J Am Coll Cardiol. 2006;47:205-207. (Pubitemid 43005187)
44. Lanas A, Fuentes J, Benito R, et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther. 2002;16:779-786. (Pubitemid 34407526)
45. Wenaweser P, Rey C, Eberli FR, et al. Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J. 2005;26:1180-1187. (Pubitemid 40863124)
46. Ibanez L, Vidal X, Vendrell L, et al. Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol Ther. 2006; 23:235-242. (Pubitemid 43382032)
47. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310:827-830.
48. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321:1183-1187.
49. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108:1682-1687.
50. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346:2033-2038. (Pubitemid 34680594)
51. Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med. 2000;343:834-839.
52. Jarvis B, Simpson K. Clopidogrel: a review of its use in the prevention of atherothrombosis. Drugs. 2000;60:347-377. (Pubitemid 30339141)
53. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329-1339.
54. Fork FT, Lafolie P, Tóth E, Lindgarde F. Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers. A gastroscopic study. Scand J Gastroenterol. 2000;35:464-469. (Pubitemid 30354084)
55. Hankey G, Sudlow CLM, Dunbabin DW. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database of Systematic Reviews. 2000;1. Art No: CD001246.
56. Walsh SJ, Spence MS, Crossman D, Adgey AA. Clopidogrel in non-ST segment elevation acute coronary syndromes: an overview of the submission by the British Cardiac Society and the Royal College of Physicians of London to the National Institute for Clinical Excellence, and beyond. Heart. 2005;91:1135-1140. (Pubitemid 41192379)
57. Harker LA, Boissel JP, Pilgrim AJ, Gent M. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Saf. 1999;21:325-335.
58. Ng FH, Wong SY, Chang CM, et al. High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. Aliment Pharmacol Ther. 2003;18:443-449.
59. Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med. 2005;352:238-244. (Pubitemid 40110812)
60. Ng FH, Wong BC, Wong SY, et al. Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk - a single-blind, randomized controlled study. Aliment Pharmacol Ther. 2004;19:359-365.
61. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502. (Pubitemid 32758501)
62. Schleinitz MD, Heidenreich PA. A costeffectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med. 2005;142:251-259.
63. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
64. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331-337. (Pubitemid 39458141)
65. Liberopoulos EN, Elisaf MS, Tselepis AD, et al. Upper gastrointestinal haemorrhage complicating antiplatelet treatment with aspirin and/or clopidogrel: where we are now? Platelets. 2006;17:1-6.
66. Barkun A, Bardou M, Marshall JK. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2003;139:843-857.
67. Palmer KR. Non-variceal upper gastrointestinal haemorrhage: guidelines. Gut. 2002;51(suppl 4):iv1-iv6.
68. Eisen GM, Baron TH, Dominitz JA, et al. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastrointest Endosc. 2002;55:775-779.
69. Zuckerman MJ, Hirota WK, Adler DG, et al. ASGE guideline: the management of low-molecular-weight heparin and nonaspirin antiplatelet agents for endoscopic procedures. Gastrointest Endosc. 2005;61:189-194.
70. Hui AJ, Wong RM, Ching JY, et al. Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: analysis of 1657 cases. Gastrointest Endosc. 2004;59:44-48.
71. Yousfi M, Gostout CJ, Baron TH, et al. Postpolypectomy lower gastrointestinal bleeding: potential role of aspirin. Am J Gastroenterol. 2004;99:1785-1789. (Pubitemid 39237509)
72. Makar GA, Ginsberg GG. Therapy insight: approaching endoscopy in anticoagulated patients. Nat Clin Pract Gastroenterol Hepatol. 2006;3:43-52.
73. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109:701-705. (Pubitemid 38222887)
74. Karvouni E, Korovesis S, Katritsis DG. Very late thrombosis after implantation of sirolimus eluting stent. Heart. 2005;91:e45.
75. Ishikawa T, Mori C, Abe Y, et al. A case report of late coronary stent thrombosis manifested as acute myocardial infarction 19 months after stenting. Jpn Heart J. 2004;45:147-152. (Pubitemid 41518934)